Michael J. Kamdar

EVP, Chief Business Officer and Member of Board of Directors

Michael J. Kamdar is a founder of VentiRx Pharmaceuticals, and currently serves as Executive Vice President and Chief Business Officer as well as a member of the Board of Directors. Prior to VentiRx, Mr. Kamdar served as Senior Vice President, Corporate Development and Finance at Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) from August 2001 through June 2005. During this time, Mr. Kamdar led a $570M transaction with Novartis that focused on the company's lead Toll-like receptor-7 (TLR7) program. This transaction was awarded "The Most Creative and Significant Deal of 2005" at the 18th Annual Biotech CEO Meeting. In addition, Mr. Kamdar played an instrumental role in the company's initial public offering in March 2004. Prior to this, Mr. Kamdar served as Anadys' Vice President, Corporate Development and Strategy, with responsibility for business development, as well as investor relations, corporate communications, and global strategic planning.

From 2000 to 2001, Mr. Kamdar was Senior Director, Business Development at Agouron Pharmaceuticals, a Pfizer Company. Mr. Kamdar was at Agouron from 1994 through 2001, which was acquired by Warner-Lambert in 1999. Mr. Kamdar held various business development positions and responsibilities at Agouron that culminated with his assumption of global responsibility for corporate partnering, in-licensing, technology acquisition, and strategic alliance efforts in the anti-infective, oncology, and ophthalmology therapeutic areas.

Prior to Agouron, Mr. Kamdar held various product management and new product planning positions for Hybritech, Inc., an Eli Lilly Company, and Centocor, Inc. Mr. Kamdar received his B.S. in Biology from St. Joseph's University and his M.B.A. from Villanova University.